Gilead Sciences Inc

GILD remains in a Stage 2 advancing phase within a broader uptrend. The primary Momentum Breakout and ongoing Lockout Rally highlight sustained institutional demand. Price has extended above rising EMAs without exhaustion, and recent pullbacks into the 9EMA/20EMA zone held as support. Under Lockout Rally dynamics, continuation participation via Buy Now is warranted, aligning with a stable approach.

• ↑HIV product sales rose 10% YoY, underpinning management’s 8% growth outlook.
• ↑FDA approval of Trodelvy in triple-negative breast cancer expands oncology franchise.
• ↓Medicare Part D reform could cut ~$900M in HIV sales, shaving 2% growth.